Top Midday Decliners

MT Newswires Live

2小時前

Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.

Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.

Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.

Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.

Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.

Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.

Price: 2.83, Change: -3.85, Percent Change: -57.63

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2668699177"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668699177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668699177?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 02:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668699177","market":"sh","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.</p><p>Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.</p><p>Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.</p><p>Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.</p><p>Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.</p><p>Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.</p><p>Price: 2.83, Change: -3.85, Percent Change: -57.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-18 02:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.</p><p>Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.</p><p>Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.</p><p>Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.</p><p>Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.</p><p>Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.</p><p>Price: 2.83, Change: -3.85, Percent Change: -57.63</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4096","symbol_name":"電氣部件與設備","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668699177","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668699177","pubTimestamp":1789670197,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Longeveron's  phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.Viant Technology  announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.Fluence Energy  cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.Price: 2.83, Change: -3.85, Percent Change: -57.63","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4096":"电气部件与设备","LU0823414478.USD":"法巴经典能源转换基金","FLNC":"Fluence Energy, Inc.","LGVN":"Longeveron Inc","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU2506951792.HKD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (HKDHDG)       ACC","LU2294711713.HKD":"BNP PARIBAS ENERGY TRANSITION \"C\" (HKD) ACC","LU0823414551.USD":"BNP PARIBAS ENERGY TRANSITION \"C\" (USD) INC","BK4023":"应用软件","DSP":"Viant Technology Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2357125470.USD":"BNP PARIBAS ENERGY TRANSITION \"CLASSIC RH\" (USDHDG) ACC","BK4139":"生物科技"},"translate_title":"午盘跌幅最大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGVN":1,"FLNC":1,"DSP":1},"content_text":"Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.Price: 2.83, Change: -3.85, Percent Change: -57.63","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}